Research organizations are launching the International Cancer Genome Consortium (ICGC) to generate genomic data on up to 50 types of cancers. Every project is expected to involve specimens from approximately 500 patients and have an estimated cost of $20 million.
The ICGC will generate a list of approximately 50 cancer types and subtypes that are of clinical significance around the globe. Members plan to assume responsibility for specific cancers. The ICGC will facilitate the exchange of information, so participants’ efforts do not duplicate each other.
Each ICGC member intends to conduct a comprehensive, high-resolution analysis of the full range of genomic changes in at least one specific type or subtype of cancer. To maximize the public benefit from ICGC member research, data will be made available to qualified investigators. In addition, all consortium participants intend not to file any patent applications or make other intellectual property claims on primary data from ICGC projects.
Currently the ICGC includes the Ontario Institute for Cancer Research, the Chinese Cancer Genome Consortium, France’s Institut National du Cancer, India’s Department of Biotechnology-Ministry of Science & Technology, Riken, Japan’s National Cancer Center, the Genome Institute of Singapore, the Wellcome Trust, the Wellcome Trust Sanger Institute, and the NIH. Australia’s National Health and Medical Research Council, Genome Canada, and the European Commission are also currently involved in the program as observers.